0 0 0
Dieser Online-Shop verwendet Cookies für ein optimales Einkaufserlebnis. Dabei werden beispielsweise die Session-Informationen oder die Spracheinstellung auf Ihrem Rechner gespeichert. Ohne Cookies ist der Funktionsumfang des Online-Shops eingeschränkt. Sind Sie damit nicht einverstanden, klicken Sie bitte hier.

Sommer, Zochodne Case Studies in Neurological Pain

ISBN: 978-0-521-69526-8

Auflage: 1st Ed.

Erscheinungsdatum: November 2012

Einband: Softcover

Seitenzahl: 148 p.

Illustrationen: 158 ill.

Verlag: Cambridge

Lieferzeit ab Ihrer Bestellung: 2-14 Tage je nach Lieferbarkeit und Verlag

Beschreibung

Pain is one of the most common symptoms of neurological disease and its appropriate management is essential to the effective care of patients. Neurological disorders differ in their specific pain phenotype, mechanisms and therapy. Case Studies in Neurological Pain addresses the specific pain issues, treatment and pathophysiology in patients with a wide spectrum of neurological disease. Clinical case studies have long been recognized as a useful adjunct to problem-based learning and continuing professional development. They emphasize the need for clinical reasoning, integrative thinking, problem-solving, communication, teamwork and self-directed learning – all desirable generic skills for health care professionals. Presenting real-life cases – covering conditions including diabetic and idiopathic polyneuropathies, focal neuropathies, multiple sclerosis and headache disorders – this book provides neurologists, neurosurgeons, pain clinic specialists and primary care physicians with an understanding of problems encountered in neurological practice. There are also chapters on mechanisms of neurological pain and new treatment guidelines.

  • Includes recommended treatment plans to aid quick and accurate treatment
  • Real-life cases facilitate understanding of the patient´s problems more accurately than data from clinical trials
  • Discusses mechanisms of pain and therapeutic challenges to guide researchers and industry in their approach to new therapies